Extension of the life span of pressure ulcer fibroblasts with recombinant human interleukin-1 beta.
Recombinant human interleukin-1 beta (rhuIL-1 beta) was investigated in a randomized, blinded placebo-controlled trial to evaluate its effect on the healing of chronic pressure ulcers. The influence of this topically applied cytokine to 26 pressure ulcer patients was correlated with tissue culture and electron microscopic evaluation. Cellular replication studies showed that low (0.01 micrograms/cm2/day) and medium (0.1 micrograms/cm2/day) concentrations of rhuIL-1 beta were not effective in extending replication in pressure ulcer fibroblasts, in vitro. Tissue culture measurements from pressure ulcer biopsies demonstrated that, after 29 days of a high level of rhuIL-1 beta treatment (1.0 micrograms/cm2/day), the cytokine was effective in extending the ability of pressure ulcer fibroblasts to replicate. Tissue culture and electron microscopy suggested that, although rhuIL-1 beta promoted increases in fibroblast numbers, the primary effect appeared to be development of the extracellular matrix. The possible direct and indirect influences of rhuIL-1 beta therapy on pressure ulcers are discussed.
Vande Berg
J S
JS
San Diego Veterans Administration Medical Center, CA 92161, USA.
Robson
M C
MC
Mikhail
R J
RJ
D002470:Cell Survival / Q000187:drug effects*; D002478:Cells, Cultured; D005347:Fibroblasts / Q000187:drug effects*; D006801:Humans; D007375:Interleukin-1 / Q000494:pharmacology*; D003668:Pressure Ulcer / Q000188:drug therapy* / Q000473:pathology; D011994:Recombinant Proteins / Q000494:pharmacology
D007375:Interleukin-1; D011994:Recombinant Proteins